MS4A1: B-lymphocyte antigen CD20
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes.
- Drugs that act on it: 18
- With a US drug page: 7
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Epcoritamab | Approved | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
| Glofitamab | Approved | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
| Mosunetuzumab | Approved | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
| Obinutuzumab | Approved | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
| Ocrelizumab | Approved | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| Ofatumumab | Approved | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
| Ublituximab | Approved | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| FBT-A05 | — | B-lymphocyte antigen CD20 cross-linking agent | Cross-linking agent | — |
| LFB-R603 | — | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| MT-3724 | — | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| Ocaratuzumab | — | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| Odronextamab | — | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| Rituximab | — | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
| Tositumomab | — | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
| Tositumomab 131I | — | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| TRU-015 | — | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| Veltuzumab | — | B-lymphocyte antigen CD20 binding agent | Binding agent | — |
| Yttrium y 90 ibritumomab tiuxetan | — | B-lymphocyte antigen CD20 binding agent | Binding agent | Boxed warning |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Neoplasm
- 0.59
- Pemphigus
- 0.53
- B-cell non-Hodgkin lymphoma
- 0.52
- Common variable immunodeficiency
- 0.48
Drugs and mechanisms are from ChEMBL CHEMBL2058 (CC BY-SA 3.0). Gene name, function (UniProt P11836, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets